AbCellera Biologics (8QQ) Q2 2026 Earnings Report

The call conveys a cautiously optimistic outlook: the company is well capitalized with substantial upfront partnership cash, large potential deal value, and multiple near-term clinical catalysts (notably ABCL635 topline readout and ABCL575 Phase I readout). Those positives are tempered by a sharp year-over-year revenue decline (~-76.5%), a wider net loss (+57.1%), increased R&D spend, and remaining scientific and placebo-related risks for the lead program. On balance, the strong liquidity position and strategic partnerships alongside clear near-term catalysts outweigh the financial pressures and programmatic risks in the short term.

Management guided that a top‑line readout for ABCL635 (postmenopausal VMS) is expected "very soon" after enrollment and initial dosing completed in June, with the Phase II top‑line reporting 4‑week data only (single dose, no re‑dosing) and they’re targeting a clinically meaningful frequency improvement of roughly 20% vs placebo and ≥2 fewer hot flashes/day; ABCL575 Phase I dosing is complete with a readout on track for Q4 (no plans to develop beyond Phase I), ABCL‑688 and ABCL386 are expected to enter Phase I/II in 2027, and one planned IND‑enabling move in H1 was missed but progress continues. Financial guidance/metrics: Q2 revenue ≈$4M (vs ≈$17M y/y), R&D ≈$46M (up ≈$7M y/y), SG&A ≈$14M (down from $22M), net loss ≈$55M (vs $35M) and loss per share $0.18; cash and marketable securities ≈$565–567M with $420M invested in short‑term securities, roughly $110M of available committed government funding (total available liquidity >$675M including unused government funding), operating cash used ≈$8M in H1 (including $56M upfront from Jazz), YTD capex ≈$6M, $7M in government grants received, and $15M invested in marketable securities this quarter. Strategic deal metrics: recent TCE collaborations bring $28M upfront from Vertex and $84M near‑term from Jazz (total >$110M upfront), $56M of Jazz upfront received to date with another $28M due, potential Jazz downstream payments >$2B and total program deal value >$4B, plus mid‑single to low‑double‑digit tiered royalties; management says liquidity supports at least the next 3 years of pipeline investment.